Program
Akt-1 Antisense Oligonucleotide WGI-0301
Also written as “WGI-0301”, “WGI-0301 at MTD/RP2D dose IV infusion, QW” and “WGI-0301 at MTD/RP2D -1 dose IV infusion, QW”.
Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Renal Cell, led by Zhejiang Haichang Biotech.
Furthest: phase 2, since Mar 1, 20244 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zhejiang Haichang Biotech | 44 open or running | phase 2since Mar 1, 2024 | Feb 8, 2022 | Dec 2026phase 2 · NCT06309485 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 8, 2022First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05267899 · 24 planned · United States
- Mar 1, 2024Phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT06309485 · 60 planned · China, Hong Kong
- Mar 16, 2026Phase 2 study in Carcinoma, Renal CellNCT07494435 · 230 planned · China
- Apr 14, 2026Phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT07540832 · 80 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT06309485
- Jun 1, 2028Primary completion: phase 2 study in Carcinoma, Renal CellNCT07494435
- Sep 2028Primary completion: phase 2 study in Advanced Hepatocellular Carcinoma (HCC)NCT07540832
TargetBeta
HLA-B →read by rule
“A lipid nanoparticle preparation of archexin, a 20-mer antisense (AS) oligodeoxynucleotide (ODN) against the proto-oncogene Akt, ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07540832Advanced Hepatocellular Carcinoma (HCC) · United States | 2 | Not yet recruiting | Sep 2028 | 80 |
| NCT07494435Carcinoma, Renal Cell · China | 2 | Not yet recruiting | Jun 1, 2028 | 230 |
| NCT06309485Advanced Hepatocellular Carcinoma (HCC) · China, Hong Kong | 2 | Recruiting | Dec 2026 | 60 |
| NCT05267899Advanced Solid Tumors · United States | 1 | Recruiting | Oct 15, 2024 | 24 |
How it is read
Names in the registry
- “WGI-0301”, 5 entries
- “WGI-0301 at MTD/RP2D dose IV infusion, QW”, 1 entry
- “WGI-0301 at MTD/RP2D -1 dose IV infusion, QW”, 1 entry
Codes read as this program: WGI0301.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 2 studies
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.